Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HF-POLARIS: NNC0487-0111 vs placebo in obese patients with heart failure with preserved or mildly reduced ejection fraction
CTR20263200Phase 3Active
- Sponsor
- Novo Nordisk
- Start
- May 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of amycretin in heart failure (HF), heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), obesity, type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started May 2026; status: active.
02
Drugs
amycretin
03
Conditions
heart failure (HF)heart failure with preserved ejection fraction (HFpEF)heart failure with reduced ejection fraction (HFrEF)obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20263200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263200.